Actively Recruiting

Age: 18Years +
All Genders
NCT06809764

Clinical Effectiveness and Safety of Trastuzumab Deruxtecan (T-DXd) in Chinese Patients With HER2m NSCLC (RERUN)

Led by Daiichi Sankyo · Updated on 2025-05-28

150

Participants Needed

23

Research Sites

103 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Trastuzumab deruxtecan (T-DXd) is an approved therapy for non-small cell lung cancer (NSCLC) in China. Despite the clinical trial evidence, there is no real-world data of T-DXd used in Chinese lung cancer patients with HER2 mutations. This real world, prospective study will assess the effectiveness and safety of T-DXd in patients with locally advanced or metastatic, HER2 mutation-positive NSCLC in real-world setting.

CONDITIONS

Official Title

Clinical Effectiveness and Safety of Trastuzumab Deruxtecan (T-DXd) in Chinese Patients With HER2m NSCLC (RERUN)

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 18 years or older at signing informed consent form
  • Pathologically confirmed unresectable and/or metastatic non-squamous non-small cell lung cancer
  • Documented activating HER2 mutation
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
  • Receiving trastuzumab deruxtecan treatment based on physician's decision, started no longer than 2 months before enrollment
Not Eligible

You will not qualify if you...

  • Prior treatment with HER2-targeted therapies, including TKIs targeting HER2 mutations except pan-HER class TKIs
  • Prior treatment with antibody-drug conjugates containing topoisomerase I targeting chemotherapy
  • Presence of spinal cord compression or clinically active CNS metastases that are untreated, symptomatic, or require corticosteroids or anticonvulsants
  • Evidence of severe or uncontrolled systemic diseases, such as uncontrolled hypertension or active bleeding disorders

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 23 locations

1

Cancer Hospital Chinese Academy of Medical Sciences

Beijing, China, 100021

Not Yet Recruiting

2

Peking University International Hospital

Beijing, China, 100125

Not Yet Recruiting

3

Beijing Cancer Hospital

Beijing, China, 100142

Not Yet Recruiting

4

Hunan Second People's Hospital

Changsha, China, 410007

Not Yet Recruiting

5

Fujian Cancer Hospital

Fuzhou, China, 350014

Not Yet Recruiting

6

Affiliated Cancer Hospital and Institute of Guangzhou Medical University

Guangzhou, China, 510060

Not Yet Recruiting

7

The First Affiliated Hospital of Sun Yat-sen University

Guangzhou, China, 510062

Not Yet Recruiting

8

Zhejiang Cancer Hospital

Hangzhou, China, 310022

Not Yet Recruiting

9

Anhui Provincial Cancer Hospital

Hefei, China, 230031

Not Yet Recruiting

10

First Affiliated Hospital of Shandong First Medical University

Jinan, China, 250014

Not Yet Recruiting

11

Cancer Hospital of Shandong First Medical University

Jinan, China, 250103

Not Yet Recruiting

12

The First Affiliated Hospital of Jinzhou Medical University

Jinzhou, China, 121001

Not Yet Recruiting

13

The First Affiliated Hospital of Nanchang University

Nanchang, China, 330000

Not Yet Recruiting

14

Guangxi Medical University Cancer Hospital

Nanning, China, 541000

Not Yet Recruiting

15

Ruijin Hospital, Shanghai Jiaotong University School Of Medicine

Shanghai, China, 200025

Not Yet Recruiting

16

Zhongshan Hospital Fudan University

Shanghai, China, 200032

Not Yet Recruiting

17

The First Hospital of China Medical University

Shenyang, China, 110001

Not Yet Recruiting

18

Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center

Shenzhen, China, 518116

Not Yet Recruiting

19

The Fourth Hospital of Hebei Medical University

Shijiazhuang, China, 050011

Not Yet Recruiting

20

Shangxi Provincial Cancer Hospital

Taiyuan, China, 030013

Actively Recruiting

21

The First Affiliated Hospital of Xiamen University

Xiamen, China, 361102

Not Yet Recruiting

22

Henan Cancer Hospital

Zhengzhou, China, 450052

Not Yet Recruiting

23

The First Affiliated Hospital of Zhengzhou University

Zhengzhou, China, 450052

Not Yet Recruiting

Loading map...

Research Team

C

Contact for Clinical Trial Information

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Clinical Effectiveness and Safety of Trastuzumab Deruxtecan (T-DXd) in Chinese Patients With HER2m NSCLC (RERUN) | DecenTrialz